EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases

Liliana Gabriela Popa iD, Ioana Dumitras, Calin Giurcaneanu, Ovidiu Berghi iD, Diana Sabina Radaschin, Cristina Iolanda Vivisenco iD, Marius Nicolae Popescu, Cristina Beiu iD

Life · 25.09.2024 · 14 (10) · 1223

DOI: 10.3390/life14101223 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 25.09.2024. Verfasst von Liliana Gabriela Popa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune blistering diseases represent a group of chronic severe, disabling, and potentially fatal disorders of the skin and/or mucous membranes, primarily mediated by pathogenic auto-antibodies. Despite their rarity, these diseases are associated with significant morbidity and mortality and profound negative impact on the patient’s quality of life and impose a considerable economic burden. Rituximab, an anti-CD-20 monoclonal antibody, represents the first line of therapy for pemphigus, regardless of severity and a valuable off-label therapeutic alternative for subepidermal autoimmune blistering diseases as it ensures high rates of rapid, long-lasting complete remission. Nevertheless, disease recurrence is the rule, all patients requiring maintenance therapy with rituximab eventually. While innate resistance to rituximab in pemphigus patients is exceptional, acquired resistance is frequent and may develop even in patients with initial complete response to rituximab, representing a real challenge for physicians. We discuss the various resistance mechanisms and their complex interplay, as well as the numerous therapeutic alternatives that may be used to circumvent rituximab resistance. As no therapeutic measure is universally efficient, individualization of rituximab treatment regimen and tailored adjuvant therapies in refractory autoimmune blistering diseases are mandatory.

Schlagwörter

Stichwörter der Autor:innen

autoimmune blistering diseasesmechanism of actionpemphigusresistancerituximab

Autor:innen und Institutionen

  • Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania.
  • Department of Dermatology, Elias Emergency University Hospital, 17 Marasti Bd., District 1, 011461 Bucharest, Romania.
  • Department of Allergy and Clinical Immunology, Colentina Clinical Hospital, 19-21 Stefan cel Mare Bd., District 2, 020125 Bucharest, Romania.
  • Department of Dermatology, Dunarea de Jos University of Medicine and Pharmacy, 25 Otelarilor Bd., 800008 Galati, Romania.
  • Department of Paediatrics, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania.
  • Department of Pediatrics, Grigore Alexandrescu Clinical Emergency Hospital for Children, 30-32 Iancu de Hunedoara Road, 011743 Bucharest, Romania.

ORCID-Profile: Liliana Gabriela Popa, Ovidiu Berghi, Cristina Iolanda Vivisenco, Cristina Beiu

Förderung

  • “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Zitieren

APA

Popa, L. G., Dumitras, I., Giurcaneanu, C., Berghi, O., Radaschin, D. S., Vivisenco, C. I., Popescu, M. N., & Beiu, C. (2024). Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases. Life, 14(10), 1223. https://doi.org/10.3390/life14101223

Vancouver

Popa LG, Dumitras I, Giurcaneanu C, Berghi O, Radaschin DS, Vivisenco CI, et al. Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases. Life. 2024;14(10):1223. doi:10.3390/life14101223

BibTeX
@article{Popa2024,
  author = {Popa, Liliana Gabriela and Dumitras, Ioana and Giurcaneanu, Calin and Berghi, Ovidiu and Radaschin, Diana Sabina and Vivisenco, Cristina Iolanda and Popescu, Marius Nicolae and Beiu, Cristina},
  title = {Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases},
  journal = {Life},
  year = {2024},
  volume = {14},
  number = {10},
  pages = {1223},
  doi = {10.3390/life14101223}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche